The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 456.20
Bid: 454.80
Ask: 455.00
Change: -2.80 (-0.61%)
Spread: 0.20 (0.044%)
Open: 460.00
High: 460.00
Low: 451.80
Prev. Close: 459.00
QQ. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Adoption of FRS 101 - Reduced Disclosure Framework

11 Feb 2016 07:00

RNS Number : 5841O
QinetiQ Group plc
11 February 2016
 

11 February 2016

 

QinetiQ Group plc

 

On 10 February 2016, QinetiQ Group plc posted a letter to shareholders, the full text of which is set out below.

 

Notification to Shareholders in accordance with Financial Reporting Standard 101

 

The purpose of this letter is to notify shareholders of the proposal to adopt a new financial reporting basis for the parent company financial statements of QinetiQ Group plc ('the Company').

 

The parent company financial statements of QinetiQ Group plc (the 'Company'), as set out on pages 137 to 139 of the QinetiQ Group plc Annual Report for the year ended 31 March 2015, were prepared in accordance with UK Generally Accepted Accounting Practice. The UK Financial Reporting Council ('FRC') has issued a new financial reporting framework which took mandatory effect for accounting periods commencing on or after 1 January 2015. Accordingly the Company is required to prepare its parent company financial statements on one of the new bases permitted by the FRC.

 

The Company proposes to adopt Financial Reporting Standard 101: Reduced Disclosure Framework ('FRS 101') for its parent company financial statements for the year ending 31 March 2016 and on an ongoing basis, until such time as the Company notifies shareholders of any change to its chosen accounting framework for the parent company financial statements. FRS 101 enables a company to use the same recognition and measurement principles of EU International Financial Reporting Standards but also take advantage of a number of specified disclosure exemptions.

 

The consolidated financial statements of the QinetiQ Group will continue to be prepared in accordance with EU International Financial Reporting Standards and are unaffected by the new financial reporting framework.

 

The Company's proposal to adopt FRS 101 for its parent company financial statements does not require shareholder approval. It is necessary, however, for the Company to notify shareholders in writing of the proposed use of the disclosure exemptions permitted under FRS 101. A shareholder or shareholders holding in aggregate 5% or more of the total allotted shares in the Company may serve objections to the use of the disclosure exemptions. Objections must be served in writing and delivered to the Company Secretary at the Company's registered office, Cody Technology Park, Ively Road, Farnborough, Hampshire GU14 0LX, United Kingdom, by no later than 10 March 2016.

 

Please note that if you do not have any objections to this proposal, you do not need to take any further action.

 

In accordance with Listing Rule 9.6.1, a copy of the notification sent to shareholders has been submitted to the National Storage Mechanism and will shortly be available at www.hemscott.com/nsm.do.

 

This announcement is made pursuant to Listing Rule 9.6.3.

 

Contact: Jon Messent, Company Secretary

Tel: 01252 392000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZMGGZLLGGVZM
Date   Source Headline
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20241:54 pmRNSDirector Declaration
5th Mar 202412:08 pmRNSDirector Declaration
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20244:00 pmRNSTotal Voting Rights
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20249:32 amRNSHolding(s) in Company
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 202411:55 amRNSResult of Meeting
5th Feb 20243:48 pmRNSDirector/PDMR Shareholding
19th Jan 20249:31 amRNSDirector/PDMR Shareholding
16th Jan 20247:00 amRNSQ3 Trading Update and Share Buyback Programme
10th Jan 20245:00 pmRNSDirector/PDMR Shareholding
12th Dec 20232:38 pmRNSDirector/PDMR Shareholding
12th Dec 20232:32 pmRNSDirector Declaration
22nd Nov 20238:29 amRNSHolding(s) in Company
20th Nov 20237:00 amRNS$170m US new business contract win
16th Nov 20237:00 amRNSInterim Results
13th Nov 20239:58 amRNSDirector/PDMR Shareholding
25th Oct 20237:23 amRNSInvestor Seminar
17th Oct 20238:00 amRNSDirector Declaration
11th Oct 20237:00 amRNSSecond Quarter Trading Update
10th Oct 20233:56 pmRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNS$127m contract win in the US (formerly Avantus)
3rd Oct 20237:00 amRNS$84m contract win in the US
28th Sep 20233:24 pmRNSDirector/PDMR Shareholding
12th Sep 20235:54 pmRNSDirector/PDMR Shareholding
31st Aug 20235:03 pmRNS$224m contract win in the US (formerly Avantus)
25th Aug 20232:23 pmRNSDirector/PDMR Shareholding
10th Aug 20234:31 pmRNSDirector/PDMR Shareholding
27th Jul 20234:45 pmRNSDirector/PDMR Shareholding
20th Jul 20232:00 pmRNSResult of AGM
20th Jul 20237:00 amRNSFirst Quarter Trading Update
11th Jul 20235:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.